Page 1 |
Save page Remove page | Previous | 1 of 59 | Next |
|
small (250x250 max)
medium (500x500 max)
Large (1000x1000 max)
Extra Large
large ( > 500x500)
Full Resolution
All (PDF)
|
This page
All
|
GLIOBLASTOMA TREATMENT WITH 2,5-DIMETHYL-CELECOXIB (DMC) IN VITRO:
– EFFECTS OF ADDITIONAL CHEMOTHERAPEUTIC DRUGS AND TUMOR MICROENVIRONMENT
– INCONSISTENCIES AMONG COMMONLY USED IN VITRO CELL GROWTH AND SURVIVAL ASSAYS
by
Nathaniel Leu Soriano
____________________________________________________________________
A Thesis Presented to the
FACULTY OF THE GRADUATE SCHOOL
UNIVERSITY OF SOUTHERN CALIFORNIA
In Partial Fulfillment of the
Requirements for the Degree
MASTER OF SCIENCE
(EXPERIMENTAL AND MOLECULAR PATHOLOGY)
December 2006
Copyright 2006 Nathaniel Leu Soriano
i
Object Description
| Title | Glioblastoma treatment with 2,5-dimethyl-celecoxib (DMC) in vitro: - effects of additional chemotherapeutic drugs and tumor microenvironment, - inconsistencies among commonly used in vitro cell growth and survival assays |
| Author | Soriano, Nathaniel Leu |
| Author email | soriano@usc.edu |
| Degree | Master of Science |
| Document type | Thesis |
| Degree program | Experimental & Molecular Pathology |
| School | Keck School of Medicine |
| Date defended/completed | 2006-08-04 |
| Date submitted | 2006 |
| Restricted until | Unrestricted |
| Date published | 2006-09-28 |
| Advisor (committee chair) | Chen, Thomas C. |
| Advisor (committee member) |
Schonthal, Axel Hofman, Florence M. |
| Abstract | 2,5-dimethyl-celecoxib (DMC) is a close structural analog of the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib (Celebrex®) that lacks COX-2 inhibitory function yet maintains all of celecoxib's anti-tumor properties. We set out to investigate the potential of combining current glioblastoma chemotherapies with DMC as a new approach to enhance glioblastoma cell killing. DMC was not only able to enhance tumor cell killing when combined with other drugs but also induced glioblastoma growth arrest and apoptosis in low glucose and hypoxic conditions which are normally associated with chemoresistance. Therefore, if DMC were used in combination it may potentially be able to reverse this chemoresistance and restore or even enhance these drugs' inhibitory effects.; In addition, we also discovered inconsistencies between the MTT assay and other in vitro cell growth and survival assays. Hence, the MTT assay should be used with caution, and its results should be supported by other available in vitro assays. |
| Keyword | DMC; glioblastoma; drug combination |
| Language | English |
| Part of collection | University of Southern California dissertations and theses |
| Publisher (of the original version) | University of Southern California |
| Place of publication (of the original version) | Los Angeles, California |
| Publisher (of the digital version) | University of Southern California. Libraries |
| Type | texts |
| Legacy record ID | usctheses-m54 |
| Contributing entity | University of Southern California |
| Rights | Soriano, Nathaniel Leu |
| Repository name | Libraries, University of Southern California |
| Repository address | Los Angeles, California |
| Repository email | cisadmin@lib.usc.edu |
| Filename | etd-Soriano-20060928 |
| Archival file | uscthesesreloadpub_Volume4/etd-Soriano-20060928.pdf |
Description
| Title | Page 1 |
| Contributing entity | University of Southern California |
| Repository email | cisadmin@lib.usc.edu |
| Full text | GLIOBLASTOMA TREATMENT WITH 2,5-DIMETHYL-CELECOXIB (DMC) IN VITRO: – EFFECTS OF ADDITIONAL CHEMOTHERAPEUTIC DRUGS AND TUMOR MICROENVIRONMENT – INCONSISTENCIES AMONG COMMONLY USED IN VITRO CELL GROWTH AND SURVIVAL ASSAYS by Nathaniel Leu Soriano ____________________________________________________________________ A Thesis Presented to the FACULTY OF THE GRADUATE SCHOOL UNIVERSITY OF SOUTHERN CALIFORNIA In Partial Fulfillment of the Requirements for the Degree MASTER OF SCIENCE (EXPERIMENTAL AND MOLECULAR PATHOLOGY) December 2006 Copyright 2006 Nathaniel Leu Soriano i |
